TICKERNERD
Menu
SRRKSRRKHealthcare · Biotechnology

SRRK Stock Forecast: Scholar Rock Holding Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$55
−0.47% on the day

The 18 Wall Street analysts covering Scholar Rock Holding Corp. hold a median 12-month price target of $60 — +8.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.7B
Ticker Nerd rank
37 / 100
Median analyst target
$60
Analysts covering
18
Revenue$0.0
Operating income−$108.9M
Net income−$109.9M
Free cash flow−$70.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.9%
1M
+6.4%
YTD
+25.8%
1Y
+74.0%
From 52W high
−7.7%
From 52W low
+98.5%
$28
$60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SRRK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Scholar Rock Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
86
Accruals
75
Value
72
Revisions
55
Volatility
49
Growth
35
Quality
20
Size
19
Issuance
7

Momentum (86): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SRRK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRRK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26SRRKHigh $76Median $60Low $48

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
18 Buy0 Hold0 Sell
Low $48Median $60High $76

The green dot is the last close — the median target sits +8.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
8 Sept 2026HC Wainwright & Co.ReiteratesBuy$65
13 Aug 2026JP MorganMaintainsOverweight—
13 Aug 2026JP MorganMaintainsOverweight$56 → $63
10 Aug 2026HC Wainwright & Co.ReiteratesBuy—
10 Aug 2026HC Wainwright & Co.ReiteratesBuy$65
10 Aug 2026WedbushReiteratesOutperform—
10 Aug 2026WedbushReiteratesOutperform$58
7 Aug 2026CitigroupMaintainsBuy$58 → $60
7 Aug 2026CitigroupMaintainsBuy—
21 July 2026WedbushReiteratesOutperform—
21 July 2026WedbushReiteratesOutperform$58
8 May 2026BarclaysMaintainsOverweight—
8 May 2026BarclaysMaintainsOverweight$53 → $55
8 May 2026HC Wainwright & Co.MaintainsBuy$58 → $65
8 May 2026HC Wainwright & Co.MaintainsBuy—
21 Apr 2026Canaccord GenuityInitiatesBuy—
1 Apr 2026WedbushMaintainsOutperform—
16 Mar 2026JP MorganMaintainsOverweight—
4 Mar 2026BarclaysMaintainsOverweight—
4 Mar 2026BMO CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRRK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SRRK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Scholar Rock Holding Corp. returned +74.0% against +17.5% for the S&P 500, dividends included.

SRRK vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26SRRKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SRRK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
6
Fundamentals

Scholar Rock Holding Corp. (SRRK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−16.8×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
26.6×

Cheaper than 4% of US stocks

EV / EBITDA
−16.0×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−167.8%

Higher than 9% of US stocks

Return on assets
−58.8%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Scholar Rock Holding Corp. (SRRK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Scholar Rock Holding Corp. has a market value of $6.7B and an enterprise value of $6.5B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$408.6M.

  • Diluted earnings per share, trailing twelve months: $−3.45.

  • Free cash flow in the twelve months to 30 June 2026: −$297.0M.

  • Shares outstanding: 121.6M.

  • Trailing P/E: −16.8×; forward P/E: −23.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Scholar Rock Holding Corp. employs 289 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

SRRK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SRRKScholar Rock Holding Corp.$6.7B
37
CAICaris Life Sciences, Inc.$6.9B
32
CGONCG Oncology, Inc.$6.4B
17
MIRMMirum Pharmaceuticals, Inc.$6.4B
67
RYTMRhythm Pharmaceuticals, Inc.$7.2B
87
TVTXTravere Therapeutics, Inc.$6.2B
87
ORKAOruka Therapeutics, Inc.$6.1B
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Scholar Rock Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRRK news & analysis

Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Benzinga · 14 Sept 2026positive

Scholar Rock Holding Corp. shares rose sharply in pre-market trading after the company announced FDA approval of ISEMBYLD (apitegromab-mstn), described as the first and only muscle-targeted treatment for children and adults with Spinal Muscular Atrophy (SMA).

Why it matters — FDA approval of its SMA treatment marks a significant regulatory milestone for Scholar Rock's lead product and a potential new commercial opportunity.

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

Business Wire · 11 Sept 2026positive

Scholar Rock announced that the FDA has approved ISEMBYLD (apitegromab-mstn), a muscle-targeted treatment for spinal muscular atrophy (SMA) in adults and children aged two years and older who are currently receiving SMN2-targeted therapy. The approval marks the first and only muscle-targeted treatment for SMA.

Why it matters — This represents a major regulatory milestone for Scholar Rock, bringing its candidate apitegromab to market and validating its myostatin-based platform in a serious neuromuscular disease.

US FDA approves Scholar Rock's muscle weakness drug

Reuters · 11 Sept 2026positive

The U.S. Food and Drug Administration on Friday approved Scholar Rock's therapy, which treats a rare genetic condition that causes muscle weakness. This marks a regulatory approval for the company's drug.

Why it matters — For Scholar Rock watchers, an FDA approval of its therapy represents a major regulatory milestone for the company's drug pipeline.

Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

Scholar Rock Holding Corporation presented at Citigroup's Biopharma Back to School Summit 2026, as covered by Seeking Alpha. The item consists of a transcript of the company's presentation at the event.

Why it matters — A Scholar Rock investor would care because presentations at industry conferences offer insight into the company's strategy and pipeline as communicated directly to the biopharma investment community.

Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise

Seeking Alpha · 7 Sept 2026positive

Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for spinal muscular atrophy, with FDA approval targeted by September 30, 2026. Manufacturing setbacks were production-related rather than efficacy- or safety-based, and an alternate fill-finish facility mitigates but does not eliminate approval risk, while SAPPHIRE trial data showed statistically significant motor function gains for nonambulatory patients.

Why it matters — For Scholar Rock watchers, this highlights apitegromab's potential as a first-in-class muscle-targeted SMA treatment with supportive efficacy data, while noting that manufacturing (rather than drug performance) remains the key remaining risk ahead of the FDA decision.

FAQ

Frequently asked questions about SRRK stock

What is the SRRK stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Scholar Rock Holding Corp. have a median 12-month price target of $60, with estimates ranging from $48 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SRRK stock a buy right now?

Of the 18 analysts covering Scholar Rock Holding Corp., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scholar Rock Holding Corp. 37 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SRRK?

As at 12 Sept 2026, Scholar Rock Holding Corp. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (86 of 100).

Will SRRK stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +8.3% from the last close, and Ticker Nerd's factor model ranks Scholar Rock Holding Corp. 37 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SRRK stock forecast for 2030?

No analyst covering Scholar Rock Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRRK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $76 over the next 12 months.

How has SRRK stock performed over the past year?

Scholar Rock Holding Corp. returned +74.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Scholar Rock Holding Corp. do?

Scholar Rock Holding Corporation Common Stock represents an equity interest in Scholar Rock Holding Corporation, a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with an emphasis on rare neuromuscular disorders such as spinal muscular atrophy (SMA). The company’s current pipeline is centered on apitegromab, its lead investigational therapy, alongside additional programs in neuromuscular and other severe disease areas where protein growth factor signaling plays a key role.

What is the latest news on SRRK?

The most recent item we track (Benzinga, 14 Sept 2026): "Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket". Scholar Rock Holding Corp. shares rose sharply in pre-market trading after the company announced FDA approval of ISEMBYLD (apitegromab-mstn), described as the first and only muscle-targeted treatment for children and adults with Spinal Muscular Atrophy (SMA).

Company

About Scholar Rock Holding Corp.

Scholar Rock Holding Corporation Common Stock represents an equity interest in Scholar Rock Holding Corporation, a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with an emphasis on rare neuromuscular disorders such as spinal muscular atrophy (SMA). The company’s current pipeline is centered on apitegromab, its lead investigational therapy, alongside additional programs in neuromuscular and other severe disease areas where protein growth factor signaling plays a key role. Scholar Rock applies its myostatin biology platform to advance treatments intended to address significant unmet medical needs in patients across pediatric and adult populations. The company is headquartered in Cambridge, Massachusetts, and its common stock is used by investors to track the market’s view of its clinical development progress, regulatory milestones, and broader biopharmaceutical execution.

CEO Mr. David L. Hallal · 289 employees · United States · https://www.scholarrock.com